Jeffrey Del Carmen

“We are very pleased with our exceptional performance in 2025. marked by full-year combined total revenues of $589 million, surpassing the upper end of our updated guidance of $565 million to $585 million.”

“Q2 marked another record-setting quarter for our commercial organization, underscoring continued strong execution across the portfolio and sustained demand for our differentiated therapies.”

“In the last quarter, our commercial team has achieved outstanding results across the board. I would like to draw your attention to our exceptional performance in this record-breaking quarter and our continued strategic efforts, which are paving the way for future successes.”

“We are very pleased with Q2 combined net revenue of $99.6 million fueled by FIRDAPSE's all-time high $64.9 million revenues and meaningful FYCOMPA revenue contributions of $34.6 million, positioning Catalyst well to achieve our revised revenue guidance of $380 million to $390 million.”

“We are pleased with the tremendous results delivered in Q3, building upon the momentum from the first half of the year. Q3 Firdapse’ net sales were $57.2 million, which represents 8% growth quarter-over-quarter, and 59.3% growth quarter versus the same quarter last year.”